MBX
MBXバイオサイエンシズ
MBX
MBXバイオサイエンシズ
MBX Biosciences, Inc. is upgraded to Buy, driven by strong canvuparatide Phase 2 data and a clear path to Phase 3 success in hypoparathyroidism. Canvuparatide's once-weekly dosing and robust efficacy
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript